Erratum: Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers (Laboratory Investigation (2012) 92 (1033-1044) DOI: 10.1038/labinvest.2012.61);Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers

Laboratory Investigation

Volumn 92, Issue 7, 2012, Pages 1033-1044

  Yun, Jiyeon ^a,b   Song, Sang Hyun ^a   Park, Jinah ^a,c   Kim, Hwang Phill ^a   Yoon, Young Kwang ^a   Lee, Kyung Hun ^a   Han, Sae Won ^a,d   Oh, Do Youn ^a,d   Im, Seock Ah ^a,d   Bang, Yung Jue ^a,d   Kim, Tae You ^a,b,d  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Seoul National University Hospital   (South Korea)

Author keywords

5 Aza CdR; cetuximab; DNA methylation; epiregulin (EREG); histone modification; human gastric cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CETUXIMAB; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; EPIREGULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DNA METHYLATION; DOWN REGULATION; DRUG POTENTIATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; STOMACH CANCER;

EID: 84863006266     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.100     Document Type: Erratum

References (43)

1. Komurasaki T, Toyoda H, Uchida D, et al. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. Oncogene 1997;15:2841-2848. (Pubitemid 28004573)
2. Eltarhouny SA, Elsawy WH, Radpour R, et al. Genes controlling spread of breast cancer to lung 00gang of 400 . Exp Oncol 2008;30:91-95. (Pubitemid 351951382)
3. Inatomi O, Andoh A, Yagi Y, et al. Regulation of amphiregulin and epiregulin expression in human colonic subepithelial myofibroblasts. Int J Mol Med 2006;18:497-503.
4. Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007;446:765-770. (Pubitemid 46582040)
5. Lee D, Pearsall RS, Das S, et al. Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage. Mol Cell Biol 2004;24:8907-8916. (Pubitemid 39313896)
6. Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009;27:5068-5074.
7. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-3237. (Pubitemid 47325606)
8. Saridaki Z, Tzardi M, Papadaki C, et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in 4/2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 2011;6:e15980.
9. Watanabe T, Kobunai T, Yamamoto Y, et al. Prediction of liver metastasis after colorectal cancer using reverse transcription-polymerase chain reaction analysis of 10 genes. Eur J Cancer 2010;46: 2119-2126.
10. Wozniak RJ, Klimecki WT, Lau SS, et al. 5-Aza-20-deoxycytidinemediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 2007;26:77-90. (Pubitemid 46067333)
11. Park J, Song SH, Kim TY, et al. Aberrant methylation of integrin alpha4 gene in human gastric cancer cells. Oncogene 2004;23: 3474-3480. (Pubitemid 38669837)
12. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010;28:1069-1078.
13. Pai AA, Bell JT, Marioni JC, et al. A genome-wide study of DNA methylation patterns and gene expression levels in multiple human and chimpanzee tissues. PLoS Genet 2011;7:e1001316.
14. Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 2011;68:1681-1702.
15. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128: 683-692. (Pubitemid 46273572)
16. Kim H, Park J, Jung Y, et al. DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells. Int J Oncol 2010;36: 1563-1572.
17. Milutinovic S, Brown SE, Zhuang Q, et al. DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation. J Biol Chem 2004;279: 27915-27927. (Pubitemid 38900060)
18. Kawamoto K, Hirata H, Kikuno N, et al. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines. Int J Cancer 2008;123:535-542. (Pubitemid 351898410)
19. Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007;8:286-298. (Pubitemid 46439286)
20. Hirst M, Marra MA. Epigenetics and human disease. Int J Biochem Cell Biol 2009;41:136-146.
21. Feng W, Yonezawa M, Ye J, et al. PHF8 activates transcription of rRNA genes through H3K4me3 binding and H3K9me1/2 demethylation. Nat Struct Mol Biol 2010;17:445-450.
22. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-1159.
23. Jung Y, Park J, Kim TY, et al. Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. J Mol Med 2007;85:1137-1148. (Pubitemid 47476731)
24. Song SH, Kim A, Ragoczy T, et al. Multiple functions of Ldb1 required for beta-globin activation during erythroid differentiation. Blood 2010;116:2356-2364.
25. Nam HJ, Kim HP, Yoon YK, et al. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett 2011;302: 155-165.
26. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2005;74:481-514. (Pubitemid 40995515)
27. Chen T, Li E. Establishment and maintenance of DNA methylation patterns in mammals. Curr Top Microbiol Immunol 2006;301:179-201. (Pubitemid 43022672)
28. Shah MY, Vasanthakumar A, Barnes NY, et al. DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res 2010;70: 5840-5850.
29. Ghoshal K, Motiwala T, Claus R, et al. HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors. PLoS One 2010;5:e10338.
30. Girault I, Tozlu S, Lidereau R, et al. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 2003;9:4415-4422. (Pubitemid 37248399)
31. Nosho K, Shima K, Irahara N, et al. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res 2009;15:3663-3671.
32. Feltus FA, Lee EK, Costello JF, et al. DNA motifs associated with aberrant CpG island methylation. Genomics 2006;87:572-579.
33. Bai S, Ghoshal K, Datta J, et al. DNA methyltransferase 3b regulates nerve growth factor-induced differentiation of PC12 cells by recruiting histone deacetylase 2. Mol Cell Biol 2005;25:751-766. (Pubitemid 40096595)
34. Cruz JJ, Ocana A, Del Barco E, et al. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 2007;18:421-430. (Pubitemid 46359619)
35. Annemans L, Van Cutsem E, Humblet Y, et al. Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan-a Belgian analysis. Acta Clin Belg 2007;62:419-425. (Pubitemid 351236175)
36. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004;22:2610-2616. (Pubitemid 41103748)
37. Hu K, Li SL, Gan YH, et al. Epiregulin promotes migration and invasion of salivary adenoid cystic carcinoma cell line SACC-83 through activation of ERK and Akt. Oral Oncol 2009;45:156-163.
38. Zhuang S, Yan Y, Daubert RA, et al. Epiregulin promotes proliferation and migration of renal proximal tubular cells. Am J Physiol Renal Physiol 2007;293:F219-F226. (Pubitemid 47345021)
39. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-153. (Pubitemid 38198742)
40. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33(Suppl):245-254. (Pubitemid 36278835)
41. Kotake Y, Zeng Y, Xiong Y. DDB1-CUL4 and MLL1 mediate oncogeneinduced p16INK4a activation. Cancer Res 2009;69:1809-1814.
42. Harrington KJ. Rash conclusions from a phase 3 study of cetuximab? Lancet Oncol 2010;11:2-3.
43. Robak T. New nucleoside analogs for patients with hematological malignancies. Expert Opin Investig Drugs 2011;20:343-359.